Clinical proof-of-concept trial of RX 5902 (Supinoxin) in patients with cancer
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs RX 5902 (Primary)
- Indications Breast cancer; Cancer; Ovarian cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 23 Feb 2017 According to a Rexahn Pharmaceuticals media release, the preliminary readout from this study anticipated later in 2017.
- 23 Feb 2017 According to a Rexahn Pharmaceuticals media release, first patient has been dosed in this phase IIa study.
- 23 Feb 2017 Status changed from planning to recruiting, according to a Rexahn Pharmaceuticals media release.